These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 32791086

  • 1. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
    Troost JP, Trachtman H, Spino C, Kaskel FJ, Friedman A, Moxey-Mims MM, Fine RN, Gassman JJ, Kopp JB, Walsh L, Wang R, Gipson DS.
    Am J Kidney Dis; 2021 Feb; 77(2):216-225. PubMed ID: 32791086
    [Abstract] [Full Text] [Related]

  • 2. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
    Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, Tuller S, Perumal K, Massengill SF, Kamil ES, Oh G, Selewski DT, Gipson P, Gipson DS.
    Clin J Am Soc Nephrol; 2018 Mar 07; 13(3):414-421. PubMed ID: 29167190
    [Abstract] [Full Text] [Related]

  • 3. Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS.
    Hogg RJ, Friedman A, Greene T, Radeva M, Budisavljevic MN, Gassman J, Gipson DS, Jefferson JA, John EG, Kaskel FJ, Moudgil A, Moxey-Mims M, Ortiz LA, Schelling JR, Schnaper W, Srivastava T, Trachtman H, Vehaskari VM, Wong C, Woronieki RP, Van Why SK, Zolotnitskaya A.
    Clin J Am Soc Nephrol; 2013 Feb 07; 8(2):211-8. PubMed ID: 23143503
    [Abstract] [Full Text] [Related]

  • 4. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.
    Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH.
    Clin J Am Soc Nephrol; 2016 Oct 07; 11(10):1752-1759. PubMed ID: 27445167
    [Abstract] [Full Text] [Related]

  • 5. Interventions for focal segmental glomerulosclerosis in adults.
    Hodson EM, Sinha A, Cooper TE.
    Cochrane Database Syst Rev; 2022 Feb 28; 2(2):CD003233. PubMed ID: 35224732
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis.
    Chiou YY, Lee YC, Chen MJ.
    Curr Med Res Opin; 2017 Aug 28; 33(8):1389-1399. PubMed ID: 28436233
    [Abstract] [Full Text] [Related]

  • 7. Steroid resistant focal segmental glomerulosclerosis: effect of arterial hyalinosis on outcome: single center study.
    Soliman AR, Maamoun H, Soliman H, Ahmed RM.
    Rom J Intern Med; 2021 Jun 01; 59(2):127-133. PubMed ID: 33565308
    [Abstract] [Full Text] [Related]

  • 8. Adiponectin in children and young adults with focal segmental glomerulosclerosis.
    Sethna CB, Boone V, Kwok J, Jun D, Trachtman H.
    Pediatr Nephrol; 2015 Nov 01; 30(11):1977-85. PubMed ID: 26115618
    [Abstract] [Full Text] [Related]

  • 9. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
    Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H, DUPRO Steering Committee and DUPLEX Investigators.
    N Engl J Med; 2023 Dec 28; 389(26):2436-2445. PubMed ID: 37921461
    [Abstract] [Full Text] [Related]

  • 10. Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis.
    Gipson DS, Troost JP, Spino C, Attalla S, Tarnoff J, Massengill S, Lafayette R, Vega-Warner V, Adler S, Gipson P, Elliott M, Kaskel F, Fermin D, Moxey-Mims M, Fine RN, Brown EJ, Reidy K, Tuttle K, Gibson K, Lemley KV, Greenbaum LA, Atkinson MA, Hingorani S, Srivastava T, Sethna CB, Meyers K, Tran C, Dell KM, Wang CS, Yee JL, Sampson MG, Gbadegesin R, Lin JJ, Brady T, Rheault M, Trachtman H.
    JAMA Netw Open; 2022 Aug 01; 5(8):e2228701. PubMed ID: 36006643
    [Abstract] [Full Text] [Related]

  • 11. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.
    Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middleton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL.
    Kidney Int; 2011 Mar 01; 79(6):678-685. PubMed ID: 21178977
    [Abstract] [Full Text] [Related]

  • 12. Clinical trial of focal segmental glomerulosclerosis in children and young adults.
    Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D'Agati VD, Friedman AL.
    Kidney Int; 2011 Oct 01; 80(8):868-78. PubMed ID: 21734640
    [Abstract] [Full Text] [Related]

  • 13. Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.
    Bagchi S, Agarwal S, Kalaivani M, Bhowmik D, Singh G, Mahajan S, Dinda A.
    Nephron; 2016 Oct 01; 132(2):81-5. PubMed ID: 26799973
    [Abstract] [Full Text] [Related]

  • 14. Urinary miR-196a predicts disease progression in patients with chronic kidney disease.
    Zhang C, Liang S, Cheng S, Li W, Wang X, Zheng C, Zeng C, Shi S, Xie L, Zen K, Liu Z.
    J Transl Med; 2018 Apr 10; 16(1):91. PubMed ID: 29636065
    [Abstract] [Full Text] [Related]

  • 15. A prospective study of collapsing focal segmental glomerulosclerosis.
    Raja R, Nada R, Yadav AK, Kumar A, Goyal A, Kumar V, Rathi M, Kohli HS, Gupta KL, Sakhuja V, Jha V.
    Ren Fail; 2016 Jul 10; 38(6):894-8. PubMed ID: 27266801
    [Abstract] [Full Text] [Related]

  • 16. Clinical Trials in FSGS: Past Challenges and New Trial Designs.
    Gipson D.
    Semin Nephrol; 2016 Nov 10; 36(6):453-459. PubMed ID: 27987544
    [No Abstract] [Full Text] [Related]

  • 17. Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.
    Greenwood AM, Gunnarsson R, Neuen BL, Oliver K, Green SJ, Baer RA.
    Nephrology (Carlton); 2017 Jul 10; 22(7):520-530. PubMed ID: 27170059
    [Abstract] [Full Text] [Related]

  • 18. Association of histologic variants in FSGS clinical trial with presenting features and outcomes.
    D'Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, Cohen AH, Gipson DS, Gassman JJ, Radeva MK, Moxey-Mims MM, Friedman AL, Kaskel FJ, Trachtman H, Alpers CE, Fogo AB, Greene TH, Nast CC.
    Clin J Am Soc Nephrol; 2013 Mar 10; 8(3):399-406. PubMed ID: 23220425
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.
    Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL.
    Kidney Int; 1999 Dec 10; 56(6):2220-6. PubMed ID: 10594798
    [Abstract] [Full Text] [Related]

  • 20. Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.
    Cheng P, Xie Q, Liu S, Liu X, Wang L, Hao CM.
    Rev Assoc Med Bras (1992); 2024 Dec 10; 70(4):e20230871. PubMed ID: 38716932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.